RxDoctor Payments Data

Robert Foster, MD

Interventional Cardiology · Birmingham, ALNPI 1720163140

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $57,125 of the $89,751 with a category attached, or 63.6%. Medtronic accounts for 68.0% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $28,354 and has fallen 99.2% since, to $219 in 2025. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$89,751in general payments, 2019–2025

Across 251 payments — averaging $357.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$61K
  • Endologix LLC$23K
  • Philips North America LLC$2K
  • Silk Road Medical, Inc.$999
  • Novartis$423
  • Boston Scientific$335
  • plus $1K from 23 others
$529,947in research payments, 2019–2025

Across 46 payments — averaging $11,521 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Veryan Medical Incorporated$523K
  • Medtronic$6K
  • Amgen$1K

What the payments were for

  • Consulting fees$23,54526%
  • Speaking & faculty fees$57,12564%
  • Travel & lodging$4,3485%
  • Food & beverage$4,7335%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$89,751 in reported general payments places this provider in the 95th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$39,926
Medicare patients
17
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$2,433
Metoprolol Succinate35$727
Isosorbide Mononitrate14$639
Atorvastatin Calcium26$387
Ranolazine ErRanolazine12$309
ClopidogrelClopidogrel Bisulfate16$214
Furosemide20$110
Metoprolol Tartrate13$94
Amlodipine Besylate15$28

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →